Li C, Li Z, Cao Y, et al. - In this open-label, single-arm, prospective pilot study, researchers tested the safety and effectiveness of tofacitinib, an oral Janus kinase inhibitor, for the treatment of nail involvement in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Participants in the study were 13 female Asian patients (means [SD] age, 39.7 [12.3] years) with SAPHO syndrome accompanied by nail lesions and active palmoplantar pustulosis who were selected from Peking Union Medical College Hospital from September 2019 to December 2019. According to findings, tofacitinib induced substantial remission of nail lesions and palmoplantar psoriasis in patients with SAPHO syndrome, followed by improved quality of life. No severe adverse events have been detected. Further follow-up studies are warranted to determine the long-term effectiveness and safety of tofacitinib for nail involvement in SAPHO syndrome.